PDL BioPharma Stock To Go Ex-dividend Monday (PDLI)

NEW YORK ( TheStreet) -- The ex-dividend date for PDL BioPharma (Nasdaq: PDLI) is Monday, March 5, 2012. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $6.52 as of 10 a.m. ET, the dividend yield is 9.4%.

The average volume for PDL BioPharma has been 2.2 million shares per day over the past 30 days. PDL BioPharma has a market cap of $889.3 million and is part of the health care sector and drugs industry. Shares are up 3.9% year to date as of the close of trading on Thursday.

PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. The company has a P/E ratio of 5.5, below the average drugs industry P/E ratio of 8.2 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates PDL BioPharma as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. However, as a counter to these strengths, we find that the company's revenue growth has not been good. You can view the full PDL BioPharma Ratings Report.

See our dividend calendar or top-yielding stocks list.
null

If you liked this article you might like

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)